

Automated purification of dual-tagged proteins

Intellectual Property Notice: Part of GE Healthcare's Life Sciences business was acquired by Danaher on 31 March 2020 and now operates under the Cytiva[™] brand. Certain collateral materials (such as application notes, scientific posters, and white papers) were created prior to the Danaher acquisition and contain various GE owned trademarks and font designs. In order to maintain the familiarity of those materials for long-serving customers and to preserve the integrity of those scientific documents, those GE owned trademarks and font designs remain in place, it being specifically acknowledged by Danaher and the Cytiva business that GE owns such GE trademarks and font designs.

cytiva.com

GE and the GE Monogram are trademarks of General Electric Company.

Other trademarks listed as being owned by General Electric Company contained in materials that pre-date the Danaher acquisition and relate to products within Cytiva's portfolio are now trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.

Cytiva and the Drop logo are trademarks of Global Life Sciences IP Holdco LLC or an affiliate. All other third-party trademarks are the property of their respective owners. © 2020 Cytiva

All goods and services are sold subject to the terms and conditions of sale of the supplying company operating within the Cytiva business. A copy of those terms and conditions is available on request. Contact your local Cytiva representative for the most current information.

For local office contact information, visit cytiva.com/contact

CY16393-09Sep20-PT

GE Healthcare

Automated purification of dual-tagged proteins

A. Andersson, A. Bergh, M. Carlsson, I. Erlandsson, J. Flensburg, M. Galin, A. Jönsson, A. Karlsson, A. Molin, S. Nyholm-Westin, and J. Simon

GE Healthcare Bio-Sciences AB, SE-751 84 Uppsala, Sweden

Dual-tagged proteins

Recombinant proteins can be designed to contain N- or C-terminal affinity tags. If including two different tags in a construct, the target protein can be purified utilizing different affinity media, producing a purer protein with a straightforward purification scheme. If different tags are positioned on each end of the protein, a dual-tagged purification scheme ensures that a full length protein is the result. If cleavage sites are included inbetween the tag and the target protein, the affinity tag can be removed.

In this study two comparisons are made. First, the same protein is purified using two different affinity columns in two different set-ups. For another dual-tagged protein, final purity is compared when using only one affinity column, relative to using two different affinity columns.

ÄKTAxpress

ÄKTAxpress™ is a compact chromatography system supporting 28 different single- or multi-step protein purification protocols. Up to four different steps can be combined with or without on-column affinity tag cleavage.

Intelligent peak detection allows collection of peaks in capillary loops prior to injection onto the next column. Each sample is initially loaded on separate affinity columns (AC). Cleaning-inplace (CIP) is performed at the end of each run on all columns used. For higher throughput, up to twelve different ÄKTAxpress systems can be run in parallel and controlled from one computer.

For dual tagged proteins three different protocols are supported by ÄKTAxpress. Intermediate desalting (DS) is optional. The last step in the two four step protocols is either DS or gel filtration (GF). Up to three different samples can be processed automatically within a single run.



Fig 1. ÄKTAxpress™ is a compact chromatography system supporting 28 different single- or multi-step protein purification protocols

AC-(DS)-AC	3 samples in 7 hours
AC-(DS)-AC-DS	2 samples in 5.5 hours
AC-(DS)-AC-GF	2 samples in 12.5 hours

Conclusions

- By combining two different affinity tags a highly pure protein is achieved.
- Automation of purification of dual-tagged proteins on ÄKTAxpress is easy and convenient.
- The order in which affinity columns are used does not affect the end purity of the tested target proteins.



Reversing the purification order

To evaluate whether the order of affinity columns in a chosen purification method matters, proteins were purified using StrepTrap[™] HP followed by HisTrap[™] HP and subsequently in the reversed order. Fig 2 highlights one such comparison. The same amount (0.9 mg) of pure protein is achieved i both experiments, but an N-terminally truncated target protein (identified by MS analysis) passed through the HisTrap HP column more slowly than non-tagged proteins (hence the two peaks seen in the flow through: Fig 2A). According to SDS-PAGE analysis the end purity of the target protein was not affected by the order of the affinity columns used (SDS-PAGE images in Fig 2A vs Fig 2B). The smaller bands observed on the SDS-PAGE are a result of protein degradation upon SDS-treatment (data not shown).

Columns:

StrepTrap HP 1 ml HisTrap HP 1 ml Sample: (Histidine),-mCherry-Strep(II) in E. coli lysate Chosen method: AC-AC on ÄKTAxpress Binding buffer (StrepTrap HP): 100 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, pH 8.0 Elution buffer (StrepTrap HP): 100 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 2.5 mM desthiobiotin, pH 8.0 Binding buffer (HisTrap HP): 20 mM phosphate, 500 mM NaCl, 5 mM Imidazole, pH 7.4 Elution buffer (HisTrap HP): 20 mM phosphate, 500 mM NaCl, 500 mM Imidazole, pH 7.4




Fig 2. Chromatograms from purification of (Histidine)₆- and Strep(II)-tagged mCherry protein (M, ~ 30 300) using the AC-AC method on ÄKTAxpress. A) StrepTrap HP followed by HisTrap HP. B) The reversed order is used. Images from the SDS-PAGE showing the end result are inserted next to each final elution peak. A low molecular weight marker is shown in the right lane.

Single versus two affinity steps

To compare purification using one tag or combining two different tags, a dual-tagged green fluorescent protein ((Histidine)₆-GFP-GST) was purified in three different ways (Fig 3A). The SDS-PAGE in Fig 3B Lane 2 shows the result from purification on HisTrap HP followed by desalting. The results show that the medium had affinity for other proteins as well. GSTrapTM 4B is much more specific in its binding (Lane 4) and the combination of the two tags (Lane 6) gave the highest purity.




Fig 3. A) Summary of performed runs and columns used. B) SDS-PAGE analysis of fractions from purification of (Histidine),-GFP-GST.

GE, imagination at work, and GE monogram are trademarks of General Electric Company. ÄKTAxpress, HisTrap, StrepTrap, GSTrap and HiPrep are trademarks of GE Healthcare companies.

This work on EGFP is done under licenses from Fisher Biolmage ApS under patent number US 6172188, Invitrogen IP Holdings Inc. under patent numbers US 5777079 and US 5804387 and Columbia University under patent number US 6146826, including foreign equivalents and pending applications. Purification and preparation of fusion proteins and affinity peptides comprising at least two adjacent histidine residues may require a license under US pat 5,284,933 and US pat 5,310,633 including foreign patents (assignee: Hoffman La Roche, Inc). StrepTrap HP has been manufactured by GE Healthcare and contains Strep-Tactin, manufactured by IBA GmbH, which has been immobilized to GE Healthcare's chromatography media. Strep-Tactin is covered by US patent number 6,103,493 and equivalent patents and patent applications in other countries. The purchase of StrepTrap HP includes a license under such patents limited to internal use, but not re-sale. Please contact IBA for further information on licenses for commercial use of Strep-Tactin. A license for commercial use of GST Gene Fusion Vectors must be obtained from Chemicon International Inc., 28820 Single Oak Drive, Temecula California 92590, USA.

© 2007 General Electric Company – All rights reserved. First published Sept. 2007.

All goods and services are sold subject to the terms and conditions of sale of the company within GE Healthcare which supplies them. A copy of these terms and conditions is available on request. Contact your local GE Healthcare representative for the most current information

GE Healthcare Limited, Amersham Place, Little Chalfont, Buckinghamshire, HP7 9NA, UK

GE Healthcare Bio-Sciences Corp., 800 Centennial Avenue, P.O. Box 1327, Piscataway, NJ 08855-1327, USA

GE Healthcare Europe GmbH, Munzinger Strasse 5, D-79111 Freiburg, Germany

GE Healthcare Bio-Sciences KK, Sanken Bldg., 3-25-1, Hyakunincho, Shinjuku-ku, Tokyo, 169-0073 Japan



Sweden

Björkgatan 30

751 84 Uppsala

imagination at work

For contact information for your local office,

www.gelifesciences.com/hitrap

GE Healthcare Bio-Sciences AB

please visit, www.gelifesciences.com/contact

www.gelifesciences.com/protein-purification